CAN
AXDX

Cetera Advisor Networks’s Accelerate Diagnostics AXDX Stock Holding History

Cetera Advisor Networks’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-115
Closed -$17K – 1357
2020
Q2 		$17K Buy
+115
New +$11.3K ﹤0.01% 2467

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Cetera Advisor Networks's AXDX Position: Q3 2020 in Review

Cetera Advisor Networks sold out of Accelerate Diagnostics (AXDX) in Q3 2020, closing a stake of 115 shares — an estimated $17K sold.

Cetera Advisor Networks first reported a position in AXDX in Q2 2020 and held it in 1 quarter. The position peaked at $17K in Q2 2020. 112 funds tracked by Wall St. Rank hold AXDX as of Q3 2020.

  • Cetera Advisor Networks reported no remaining Accelerate Diagnostics position as of Q3 2020 after selling out during the quarter.
  • Cetera Advisor Networks sold 115 Accelerate Diagnostics shares in Q3 2020, an estimated $17K.
  • Cetera Advisor Networks first reported a position in Accelerate Diagnostics in Q2 2020 and held it in 1 quarter.
  • Cetera Advisor Networks's Accelerate Diagnostics position peaked at $17K in Q2 2020.
  • 112 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2020.

Based on Cetera Advisor Networks's 13F filing for Q3 2020, filed 13 Nov 2020.